Table 1 Reductions in mean sitting DBP (msDBP) and mean sitting DBP (msSBP)
Outcome | No. of SRs | No. of original studies | No. of cases/ controls | Follow-up range (weeks) | Estimate (95%CI) | P- value | 95%PI | I2(P*) | Egger’s P value |
|---|---|---|---|---|---|---|---|---|---|
msDBP | |||||||||
 aliskiren75mg vs placebo | 1 | 5 | 821/279 | 8–13 | − 2.05 [− 3.13,-0.96] | < 0.001 | [− 3.81,-0.28] | 0%(0.73) | 0.043 |
 aliskiren150mg vs placebo | 1 | 12 | 2665/1118 | 8–26 | −3.19 [−4.02, -2.37] | < 0.001 | [−5.57,-0.82] | 47%(0.04) | 0.798 |
 aliskiren300mg vs placebo | 1 | 10 | 2193/808 | 8–26 | −4.51 [−5.27, −3.76] | < 0.001 | [− 5.97, − 3.06] | 17%(0.29) | 0.359 |
 aliskiren600mg vs placebo | 1 | 2 | 296/97 | 8 | −5.86 [−7.73, -3.99] | < 0.0001 | NA | 0%(0.57) | NA |
 aliskiren vs ARBs (low dose) | 2 | 4 | 648/532 | 4–8 | 0.07 [−0.94,1.09] | 0.89 | [−2.15,2.30] | 0%(0.48) | 0.12 |
 aliskiren vs ARBs (low to high dose) | 2 | 5 | 923/944 | 8–12 | −0.25 [−2.32,1.82] | 0.81 | [−7.82,7.31] | 82% (0.0002) | 0.272 |
 aliskiren vs ARBs (high dose) | 2 | 3 | 241/122 | 8 | −0.65 [−2.52, 1.23] | 0.5 | [−12.79,11.49] | 0%(0.89) | 0.293 |
 aliskiren vs ACEIs | 2 | 3 | 796/786 | ≥8 | −1.19[− 1.99, −0.38] | 0.004 | [−6.42,4.05] | 0%(0.53) | 0.687 |
 aliskiren vs amlodipine | 1 | 1 | 203/181 | 8 | 3.63 [1.85,5.41] | < 0.0001 | NA | NA | NA |
 aliskiren vs HCTZ | 1 | 1 | 183/176 | 8 | −0.9 [−2.56,0.76] | 0.29 | NA | NA | NA |
 aliskiren vs atenolol | 1 | 1 | 231/231 | 12 | 2.4 [0.74,4.06] | 0.004 | NA | NA | NA |
 Aliskiren150mg vs 75 mg | 1 | 5 | 830/824 | 8–13 | −0.8 [−1.58,-0.03] | 0.04 | [−2.06,0.04] | 0%(0.45) | 0.944 |
 aliskiren300mg vs 150 mg | 1 | 10 | 2193/2195 | 8–26 | −1.75 [−2.31, − 1.20] | < 0.001 | [− 2.88,-0.63] | 20%(0.26) | 0.584 |
 aliskiren600mg vs 300 mg | 1 | 2 | 296/296 | 8 | −0.68[−2.03,0.67] | 0.449 | NA | 33%(0.22) | NA |
msSBP | |||||||||
 aliskiren75mg vs placebo | 1 | 5 | 821/279 | 8–13 | −2.97[−4.76, -1.18] | 0.001 | [−5.88,-0.66] | 0%(0.57) | 0.253 |
 aliskiren150mg vs placebo | 1 | 12 | 2665/1121 | 8–26 | −5.93[−6.94, -4.91] | < 0.001 | [−7.93,-3.92] | 17%(0.28) | 0.674 |
 aliskiren300mg vs placebo | 1 | 10 | 2199/810 | 8–26 | −7.91 [−9.15, −6.67] | < 0.001 | [−10.48,-5.33] | 22%(0.24) | 0.693 |
 aliskiren600mg vs placebo | 1 | 2 | 296/97 | 8 | −11.35[− 14.43,-8.27] | < 0.00001 | NA | 0%(0.62) | NA |
 aliskiren vs ARBs (low dose) | 2 | 4 | 648/532 | 4–8 | 1.25 [−0.29,2.78] | 0.111 | [−2.57,5.06] | 6%(0.36) | 0.661 |
 aliskiren vs ARBs (low to high dose) | 2 | 5 | 923/944 | 8–12 | −1.19[−4.09, 1.70] | 0.42 | [−11.46,9.08] | 77% (0.002) | 0.242 |
 aliskiren vs ARBs (high dose) | 2 | 3 | 241/122 | 8 | 0.24 [−2.29, 2.76] | 0.85 | [−16.10,16.57] | 0%(0.65) | 0.841 |
 aliskiren vs ACEIs | 2 | 4 | 1253/1230 | ≥8 | −2.37[−3.48, −1.26] | < 0.0001 | [−4.83,0.04] | 0%(0.59) | 0.123 |
 aliskiren vs amlodipine | 1 | 1 | 203/181 | 8 | 5.67 [2.86,8.48] | < 0.0001 | NA | NA | NA |
 aliskiren vs HCTZ | 1 | 1 | 183/176 | 8 | −1.4 [−4.04,1.24] | 0.3 | NA | NA | NA |
 aliskiren vs atenolol | 1 | 1 | 231/231 | 12 | −0.08 [−3.02,2.86] | 0.96 | NA | NA | NA |
 aliskiren150mg vs 75 mg | 1 | 5 | 830/821 | 8–13 | −1.89 [−3.34, −0.43] | 0.011 | [−5.37,1.59] | 23%(0.27) | 0.872 |
 aliskiren300mg vs 150 mg | 1 | 10 | 2199/2195 | 8–26 | −2.57 [−3.72, −1.42] | < 0.0001 | [− 5.87,0.73] | 52%(0.03) | 0.921 |
 aliskiren600mg vs 300 mg | 1 | 2 | 296/296 | 8 | −0.61 [−2.78, 1.56] | 0.581 | NA | 0%(0.60) | NA |